BioNTech SE (22UA) — Capital Reinvestment Ratio
Latest as of December 2025:
0.20x
BioNTech SE (22UA) has a Capital Reinvestment Ratio of 0.20x as of December 2025, meaning it reinvests 0% of its operating cash flow (€309.50 Million) in capital expenditures (€62.10 Million). See BioNTech SE free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.20x
Capex / Operating Cash Flow
Operating Cash Flow
€309.50 Million
EUR
Capital Expenditures
€62.10 Million
EUR
Data as of
Dec 2025
Most recent filing
BioNTech SE Capital Reinvestment Ratio (2021–2025)
This chart tracks BioNTech SE's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for BioNTech SE (2021–2025)
Year-by-year Capital Reinvestment Ratio for BioNTech SE from 2021 to 2025. For live market cap and broader valuation context, see BioNTech SE (22UA) total market value.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.64x | €456.00 Million | €749.00 Million | ▼ -24.6% |
| 2024 | 2.18x | €207.70 Million | €452.30 Million | ▲ +1558.0% |
| 2023 | 0.13x | €5.37 Billion | €705.50 Million | ▲ +390.9% |
| 2022 | 0.03x | €13.58 Billion | €363.30 Million | ▼ -81.3% |
| 2021 | 0.14x | €889.70 Million | €127.50 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow